A Phase II Study of ISIS 766720 in People with Acromegaly

Share
Print

Full Title

An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly

Purpose

The purpose of this study is to assess the safety and effectiveness of the drug ISIS 766720 to treat acromegaly due to a pituitary tumor. People with acromegaly make too much growth hormone, which raises levels of a hormone called insulin-like-growth factor-1 (IGF-1). High levels of IGF-1 in the blood can cause abnormal growth of tissue and bone.

ISIS 766720 is designed to help lower the amount of IGF-1 in the blood. It is given by subcutaneous (under the skin) injection.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have acromegaly that is not currently being treated with medication.
  • Patients must have had pituitary surgery 3 or more months before entering the study (or have been considered for surgery and couldn’t have it).
  • This study is for patients ages 18-75.

For more information about this study and to inquire about eligibility, please contact Dr. Eliza Geer at 646-608-3797.

Protocol

21-027

Phase

II

Investigator

Co-Investigators